Novartis AG

Novartis announced that its Phase III GCAptAIN study of Cosentyx (secukinumab) failed to achieve sustained remission at Week 52 in adults with newly diagnosed or relapsing giant cell arteritis.

House Judiciary Committee subpoenaed former Pfizer executive Dr. Philip Dormitzer over allegations that senior Pfizer executives deliberately slowed COVID-19 vaccine clinical testing before the 2020 election.

The FDA is revising labeling for all extended-release ADHD stimulants to include warnings about weight loss and adverse reactions in children under six years old.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

A federal court ruled against Johnson & Johnson's proposal to shift from upfront drug discounts to a rebate model in the 340B Drug Pricing Program, which requires pharmaceutical manufacturers to sell outpatient drugs at reduced prices to healthcare providers serving low-income and rural populations.

Torrent Pharma is in advanced talks with KKR to acquire JB Chemicals and Pharmaceuticals for approximately Rs 20,734.61 crore ($2.4 billion), marking its largest acquisition to date.

The FDA eliminated Risk Evaluation and Mitigation Strategy (REMS) programs and reduced post-treatment monitoring from four weeks to two weeks for Bristol Myers Squibb's CAR T-cell therapies Breyanzi and Abecma.

Incyte has appointed Bill Meury as its new CEO, effective immediately, replacing Hervé Hoppenot who led the cancer and blood disease drugmaker for 11 years.

ProFound Therapeutics announced a four-year strategic collaboration with Novartis to discover novel cardiovascular therapeutics using its ProFoundry Platform to mine the expanded human proteome.

Vor Bio acquired exclusive global rights (excluding Greater China) to develop and commercialize telitacicept, a dual-target fusion protein approved in China for multiple autoimmune diseases including generalized myasthenia gravis.